News for Mayne Pharma Group Limited (MAYNF)

Sol-Gel Technologies (SLGL) has struck a significant agreement with a Mayne Pharma Group (MAYNF) subsidiary, transferring the U.S. rights to its dermatological

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete

**media[598085]**

Release Date: February 25, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revenues inc

Rising Prevalence of Chronic Pain Conditions and the Geriatric Population Drive Morphine Market Growth...

Visiongain has published a new report entitled Clinical Trial Supply and Logistics Market for Pharma 2024-2034: Forecasts by Type (CTS Manufacturing, CTS...

The medical health awareness of an individual regarding his sex health has been increasing recently. The main reason behind this is the knowledge given to...

Mithra reports full year 2023 financial results Revenues were EUR 40.2 million, down from the 2022 result of EUR 67.0 million which was positively...

Feb 25, 2024 / 10:00PM GMTOperator Thank you for standing by, and welcome to the Mayne Pharma Group Limited half year 2024 results call. (Operator Instructions)

The Global Topical Antibiotics Market Size was Valued at USD 5.25 Billion in 2023 and the Worldwide Topical Antibiotics Market Size is Expected to Reach...

Evolving regulations regarding antibiotic use and manufacturing standards impact market dynamics and product offerings....

Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares were pledged to the secured lenders of...

Mithra sells shares in Mayne Pharma Mithra sold all 4,221,815 shares it held in Mayne Pharma for EUR ~12.8 millionAs the Mayne Pharma shares...

Visiongain has published a new report entitled Dermatological Drugs Market Report 2024-2034: Forecasts by Route of Administration (Topical, Oral,...

Improve Patients Respiratory Conditions and Reduce Irritation during Throat Infection. US anticipates 4.80% CAGR, driven by seasonal cough and cold issues,...

Key Companies Covered in the Global Hedgehog Pathway Inhibitors Market Research Report by Research Nester are Mayne Pharma Group Limited, PellePharm, Inc.,...